These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33137247)

  • 1. Association of PET-based stages of amyloid deposition with neuropathological markers of Aβ pathology.
    Teipel SJ; Temp AGM; Levin F; Dyrba M; Grothe MJ;
    Ann Clin Transl Neurol; 2021 Jan; 8(1):29-42. PubMed ID: 33137247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
    Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
    Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of amyloid distribution by [
    Thal DR; Beach TG; Zanette M; Lilja J; Heurling K; Chakrabarty A; Ismail A; Farrar G; Buckley C; Smith APL
    Acta Neuropathol; 2018 Oct; 136(4):557-567. PubMed ID: 30123935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of Striatal Amyloid Plaques with [18F]flutemetamol: Validation with Postmortem Histopathology.
    Beach TG; Thal DR; Zanette M; Smith A; Buckley C
    J Alzheimers Dis; 2016 Mar; 52(3):863-73. PubMed ID: 27031469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease.
    Sabbagh MN; Fleisher A; Chen K; Rogers J; Berk C; Reiman E; Pontecorvo M; Mintun M; Skovronsky D; Jacobson SA; Sue LI; Liebsack C; Charney AS; Cole L; Belden C; Beach TG
    Arch Neurol; 2011 Nov; 68(11):1461-6. PubMed ID: 22084131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.
    Choi SR; Schneider JA; Bennett DA; Beach TG; Bedell BJ; Zehntner SP; Krautkramer MJ; Kung HF; Skovronsky DM; Hefti F; Clark CM
    Alzheimer Dis Assoc Disord; 2012; 26(1):8-16. PubMed ID: 22354138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography.
    Wolk DA; Zhang Z; Boudhar S; Clark CM; Pontecorvo MJ; Arnold SE
    J Neurol Neurosurg Psychiatry; 2012 Sep; 83(9):923-6. PubMed ID: 22791901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of florbetapir-PET for imaging beta-amyloid pathology.
    Clark CM; Schneider JA; Bedell BJ; Beach TG; Bilker WB; Mintun MA; Pontecorvo MJ; Hefti F; Carpenter AP; Flitter ML; Krautkramer MJ; Kung HF; Coleman RE; Doraiswamy PM; Fleisher AS; Sabbagh MN; Sadowsky CH; Reiman EP; Zehntner SP; Skovronsky DM;
    JAMA; 2011 Jan; 305(3):275-83. PubMed ID: 21245183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum.
    Murray ME; Lowe VJ; Graff-Radford NR; Liesinger AM; Cannon A; Przybelski SA; Rawal B; Parisi JE; Petersen RC; Kantarci K; Ross OA; Duara R; Knopman DS; Jack CR; Dickson DW
    Brain; 2015 May; 138(Pt 5):1370-81. PubMed ID: 25805643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques.
    Driscoll I; Troncoso JC; Rudow G; Sojkova J; Pletnikova O; Zhou Y; Kraut MA; Ferrucci L; Mathis CA; Klunk WE; O'Brien RJ; Davatzikos C; Wong DF; Resnick SM
    Acta Neuropathol; 2012 Dec; 124(6):823-31. PubMed ID: 22864813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different aspects of Alzheimer's disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia.
    Thal DR; Ronisz A; Tousseyn T; Rijal Upadhaya A; Balakrishnan K; Vandenberghe R; Vandenbulcke M; von Arnim CAF; Otto M; Beach TG; Lilja J; Heurling K; Chakrabarty A; Ismail A; Buckley C; Smith APL; Kumar S; Farrar G; Walter J
    Acta Neuropathol Commun; 2019 Nov; 7(1):178. PubMed ID: 31727169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.
    Okamura N; Yanai K
    IDrugs; 2010 Dec; 13(12):890-9. PubMed ID: 21154149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Principal-Component Analysis-Based Measures of PET Data Closely Reflect Neuropathologic Staging Schemes.
    Blazhenets G; Frings L; Sörensen A; Meyer PT;
    J Nucl Med; 2021 Jun; 62(6):855-860. PubMed ID: 33097630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology.
    Thal DR; Beach TG; Zanette M; Heurling K; Chakrabarty A; Ismail A; Smith AP; Buckley C
    Alzheimers Dement; 2015 Aug; 11(8):975-85. PubMed ID: 26141264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
    Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
    Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of TDP-43 Pathology with Global and Regional 18F-Florbetapir PET Signal in the Alzheimer's Disease Spectrum.
    Teipel SJ; Temp AGM; Levin F; Dyrba M; Grothe MJ;
    J Alzheimers Dis; 2021; 79(2):663-670. PubMed ID: 33337372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Amyloid-plaque imaging of the brain using PET].
    Ossenkoppele R; Tolboom N; Pijnenburg YA; Lammertsma AA; Scheltens P; van Berckel BN
    Ned Tijdschr Geneeskd; 2011; 155():A2981. PubMed ID: 21586182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal validity of PET-based staging of regional amyloid deposition.
    Jelistratova I; Teipel SJ; Grothe MJ
    Hum Brain Mapp; 2020 Oct; 41(15):4219-4231. PubMed ID: 32648624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.
    Clark CM; Pontecorvo MJ; Beach TG; Bedell BJ; Coleman RE; Doraiswamy PM; Fleisher AS; Reiman EM; Sabbagh MN; Sadowsky CH; Schneider JA; Arora A; Carpenter AP; Flitter ML; Joshi AD; Krautkramer MJ; Lu M; Mintun MA; Skovronsky DM;
    Lancet Neurol; 2012 Aug; 11(8):669-78. PubMed ID: 22749065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.